Protective antibody response produced by the chickens vaccinated with green coloured thermostable Newcastle disease virus.
The efficacy of green-coloured (GC) I-2 Newcastle disease vaccine was determined in the present study. I-2 vaccine was mixed with a green coloured dye and stored at 4 degrees C for 6 months while assayed for the virus infectivity at a monthly interval. Chickens were vaccinated with the GC vaccine by eye drop. Serum samples were collected from all birds before and after vaccination at weekly interval for 4 weeks and tested for haemagglutination-inhibition (HI) antibody against Newcastle disease virus (NDV). These chickens were challenged with NDV virulent strain four weeks after vaccination. The results showed that there was no difference between the infectivity titres of GC and uncoloured vaccines. However, chickens vaccinated with GC vaccine produced higher HI antibody titres than chickens vaccinated with uncoloured vaccine. Results from the challenge trial showed that all vaccinated chickens survived whereas all unvaccinated chickens died. The findings from this study have shown that the GC vaccine is safe and produced protective antibodies against NDV in vaccinated chickens.
Wambura
P N
PN
Department of Veterinary Microbiology and Parasitology, Sokoine University of Agriculture, P. O. Box 3019, Chuo Kikuu, Morogoro, Tanzania. phil_wambura@yahoo.com
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D000917:Antibody Formation; D002645:Chickens / Q000821:virology*; D004396:Coloring Agents; D004196:Disease Outbreaks / Q000517:prevention & control / Q000662:veterinary; D004198:Disease Susceptibility; D006385:Hemagglutination Inhibition Tests / Q000662:veterinary; D009521:Newcastle Disease / Q000276:immunology / Q000517:prevention & control*; D009522:Newcastle disease virus / Q000276:immunology* / Q000472:pathogenicity; D011201:Poultry Diseases / Q000517:prevention & control*; D011897:Random Allocation; D016896:Treatment Outcome; D014611:Vaccination / Q000379:methods / Q000662:veterinary; D014765:Viral Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D014774:Virulence
D000914:Antibodies, Viral; D004396:Coloring Agents; D014765:Viral Vaccines